Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer

NSCLC Clinical Trial

Official title:

Feasibility of Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05909137
• Other study ID #: XQonc-022
• Status: Not yet recruiting
• Start date: September 2024
• Est. completion date: December 2026

Study information

• Verified date: February 2024
• Source: Xinqiao Hospital of Chongqing
• Contact: jianguo sun, Phd
• Phone: 023-68774490
• Email: sunjg09[@]aliyun.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Simultaneous radiotherapy followed by adjuvant immunotherapy is the standard treatment modality of unresectable stage III NSCLC. Our preliminary study confirmed that the treatment of CTV-omitted IMRT regimen did not compromise the PFS or OS and significantly reduced the incidence of severe radiation pneumonia and radiation esophagitis. The purpose of this study was to observe the role of radiotherapy modalities that omit CTV in the context of immunotherapy for NSCLC.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 60
• Est. completion date: December 2026
• Est. primary completion date: September 2026
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• •Patients with advanced (Stage IIIA or IIIB AJCC 7) NSCLC that was histologically or cytologically inoperable
• ECOG whole body status (performancestatus,PS) level 0 or 1
• The estimated survival time is more than 12 weeks, 18 ~80 years old
• Laboratory results within 2 weeks prior to radiotherapy met the following criteria: ? Neutrophil count > 1,500/ MCL Heathko-Pilot Oncology Research Fund; ? Platelet > 50,000/ MCL; ? Total bilirubin < 1.5 times of the normal upper limit value; ?AST(SGOT)/ALT(SGPT) < 2.5 times of the normal upper limit; ? Serum creatinine < 1.5 times of the normal upper limit value; ? The results of coagulation function examination were within the normal range
• Women of childbearing age must have taken reliable contraceptive measures or conducted pregnancy tests (serum or urine) within 7 days before admission, and the results are negative, and are willing to use appropriate methods of contraception during the trial period and 8 weeks after the last administration of the trial drug. For men, they must agree to use appropriate methods of contraception or surgical sterilization during the trial period and 8 weeks after the last administration of the trial drug
• Understand and voluntarily sign written informed consent
• The investigator judged that the patient had good compliance

Exclusion Criteria:

• Malignant pleural/pericardial effusions, previous thoracic radiotherapy or chemotherapy
• Uncontrolled concurrent diseases, including but not limited to symptomatic congestive heart failure, unstable angina pectoris and myocardial infarction, uncontrolled grade III hypertension, liver insufficiency, renal insufficiency, uncontrolled diabetic blood sugar, arrhythmia, mental illness or social condition, etc.
• Pregnant or nursing women
• The patient has no history of intracranial hemorrhage or spinal cord hemorrhage
• HIV-positive patients receiving combination antiretroviral therapy
• Active tuberculosis
• Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study
• Prior allogeneic stem cell or solid organ transplantation
• Researchers determine other conditions that may affect the conduct of clinical studies and the determination of their findings

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Immunotherapy
• Intensity Modulated Radiation Therapy
• NSCLC
• Radiotherapy

Intervention

Radiation:
• IMRT+adjuvant immunotherapy
The enrollment was randomly (1:1) assigned into the study group with CTV-omitted IMRT and the control group with CTV-delineated IMRT using a random number table.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Xinqiao Hospital of Chongqing

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free survival	The time between randomization and the first occurrence of disease progression or die	through study completion,up to 12 weeks
Primary	radiation respiratory events or esophagitis with grade 3 or higher		after radiation therapy,up to 1 year
Secondary	Overall survival	Time from randomization to death from any cause	through study completion, an average of 2 year